« Back
Home /
CDK-8 Human - Recombinant Human cyclin-dependent kinase 8 (2ug)

CDK-8 Human - Recombinant Human cyclin-dependent kinase 8 (2ug)

Manufacturer	AVIVA Systems Biology
Category	Oncology Neuroscience Neural Lineage Markers By Cell Type Blastoma Carcinoma Peptides & Proteins Recombinant Proteins Cell Biology Cell Status Immunoprecipitation Western Blot ELISA Proliferation By Organ Bladder Cancer
Type	Proteins
Specific against	other
Format	CDK8 is supplied at 0.1mg/ml in a buffer containing 25 mM HEPES, pH 7.9, 125mM KCI, 0.5% TX-100 and 50% glycerol.
Applications	WB, IP, ELISA
Amount	2ug
Host	E.coli
Item no.	OPPA01169
eClass 6.1	34160400
eClass 9.0	42020190
Available
Description	CDK8, Recombinant Human cyclin-dependent kinase 8
Gene symbol	CDK8
Alias symbols	Cell division protein kinase 8, EC 2.7.11.22, EC 2.7.11.23, Protein kinase K35, CDK-8, K35, MGC126074, MGC126075, CDK8, CDK-8 Human, Cyclin-Dependent Kinase 8 Human Recombinant
Gene_id	1024
Reconstitution and storage	Store at 4C if entire vial will be used within 1-2 weeks. Store, frozen at -20C for longer periods of time. Avoid multiple freeze-thaw cycles.
Description of target	Recombinant Human cyclin-dependent kinase 8
Purity	Greater than 90% as determined by SDS-PAGE.
Application info	CDK-8 can be used directly as a positive control in Western blotting, ELISA, immunoprecipitation and other immunological experiments. The biological activity of this product has not yet been tested.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 2ug

available

Delivery expected until 5/30/2024